Compare TBLA & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | OGN |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2020 |
| Metric | TBLA | OGN |
|---|---|---|
| Price | $3.50 | $13.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $5.00 | ★ $11.40 |
| AVG Volume (30 Days) | 1.8M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 220.00 | 0.95 |
| Revenue | $1,912,040,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $7.63 | $0.45 |
| Revenue Next Year | $5.25 | $1.67 |
| P/E Ratio | ★ $0.02 | $14.44 |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $2.84 | $5.69 |
| 52 Week High | $5.71 | $13.79 |
| Indicator | TBLA | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 59.92 |
| Support Level | $2.97 | $13.46 |
| Resistance Level | $3.94 | $13.79 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 20.87 | 70.00 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.